32 results about "Hepatic lipase" patented technology

Provided is a compound represented by the formula (1):

wherein R¹ and R² are each independently a hydrogen atom or a straight chain alkyl group having a carbon number of 1-3, R³ is a hydrogen atom, an alkyl group having a carbon number of 1-4, an alkoxyalkyl group, an aryl group, a halogen atom or a haloalkyl group, or a pharmaceutically acceptable salt thereof, which has, unlike known PGI₂ analogs, a selective EP4 agonist action, and a medicament containing the compound, which is useful for the prophylaxis and/or treatment of immune diseases, diseases of the digestive tract, cardiovascular diseases, cardiac diseases, respiratory diseases, neurological diseases, ophthalmic diseases, renal diseases, hepatic diseases, bone diseases, skin diseases and the like.

The present invention belongs to the field of medicine technology, and is especially one kind of medicine composition for treating liver diseases and its preparation process. The medicine composition is prepared with wolfberry fruit 50- 1000 weight portions, angelica 50-1000 weight portions, and glycyrrhizic acid or its pharmaceutically acceptable salt 1-50 weight portions; or with wolfberry fruit polysaccharide 2.5-50 weight portions, angelica polysaccharide 1-20 weight portions, and glycyrrhizic acid or its pharmaceutically acceptable salt 1-50 weight portions. It may be prepared into any pharmaceutically acceptable forms, preferably orally taken preparation and injection. It is used mainly for treating various liver diseases, including viral hepatitis, medicinal liver injury, fatty liver, alcohol liver, etc.

The present invention provides methods of administering a Dendrobium polyphenol in an amount effective to lower blood sugar, treat hepatic disease, obesity or diabetes. Exemplary hepatic disease includes fibrosis, fatty liver and hepatitis. Moreover, the Dendrobium polyphenol is extracted from the plants of the genus Dendrobium.

The invention concerns a method for early diagnosis of hepatic diseases, which consists in determining in the samples of the diseased subjects, the presence of a apolipoprotein AI (Apo-AI) isoform, having oxidised W50, W108, and M112 residues. The inventive method is useful for diagnosing hepatocellular carcinoma and hepatitis B.

The invention relates to a method for simultaneously detecting 32 labeled single nucleotide polymorphism (SNP) loci. In the method, adducin-1, platelet endothelial cell adhesion molecule-1 (PECAM-1), C-reactive protein (CRP), endothelial constitutive nitric oxide synthase (ecNOS), plasma cell membrane glycoprotein-1 (PC-1), L-selectin, G-protein beta3 subunit gene, angiotensin I converting enzyme (ACE), angiotensin II type 1 receptor gene, proangiotensin, methylenetetrahydrofolate reductase (MTHFR) and hepatic lipase gene which are published on an international haplotype diagram engineering database are selected for detecting 32 labeled single nucleotide polymorphisms of the Han nationality in China; three primers are designed for each single nucleotide polymorphism (two PCR amplification primers and one extension primer); and the single nucleotide polymorphism loci are subjected to genotyping through polymerase chain reaction (PCR) amplification, extension and hybridization and by applying an SNP stream genotyping system. The detection method has the advantages of quickness, accuracy, high throughput, simple operation, microscale and the like.

The invention relates to a miRNA expression model for diagnosing hepatic diseases independently. In the invention, an expression model of a miR-885-5p which is one of the circulating miRNAs associated with hepatic diseases is built by analyzing the types and relative expression levels of potential circulating miRNAs in a serum sample of a patient with cirrhosis or hepatocellular carcinoma and comparing the expression levels of the potential circulating miRNAs with the expression abundance of the circulating miRNAs in healthy reference serum. The model is formed by the expression indexes of the miR-885-5p, wherein the expression level of the miR-885-5p is higher than that of a healthy reference and is less tan 0.0001. ROC curve analysis shows that the hepatic disease HCC, LC and CHB identification efficacy AUC of the miR-885-5p and the healthy reference is 0.904, and the sensitivity and specificity of the miR-885-5p and the healthy reference are 90.5 percent and 79.2 percent respectively.

The invention discloses an application of E-10-hydroxy-2-decenoic acid in preparation of medicines or healthcare products for hepatic disease, and relates to the technical field of applications of hydroxy-containing unsaturated compounds in which carboxyl is connected to a non-ring carbon. The hepatic disease relates to fatty liver, hepatitis or liver cirrhosis. The E-10-hydroxy-2-decenoic acid has definite treatment or aided treatment functions for the hepatic disease, can be used for preparation of the medicines or healthcare products which are used for treatment or aided treatment of the hepatic disease, and has advantages of low cost, good effects, low using amount, and no side or toxic effects.

The invention discloses applications of protopanaxatriol derivatives or pharmaceutically formable salts thereof and protopanaxatriol or pharmaceutically formable salts of the protopanaxatriol in preparation of medicines for treating a hepatic disease. An in-vitro anti-liver fibrosis cell test proves that these compounds have relatively good anti-liver fibrosis activity, can be used as active components of anti-liver fibrosis medicines, and can be applied widely.

The disclosure provides oral compositions and methods of using such compositions in treating subjects infected with one or more hepatic disorders. The compositions include lysates or cell wall extracts of one or more gram positive bacteria, exhibit particular activity against hepatitis C virus (HCV), and may be useful in treating those infected with HCV as well as other hepatic diseases or disorders. Also described are methods of treating a hepatic disease or disorder by administering a therapeutically effective amount of at least one therapeutically active agent capable of upregulating or downregulating the Complement system pathway, wherein the therapeutically active agent enhances the formation of one or more convertase enzymes.

Disclosed are: a compound which has excellent metabolic stability and selectively binds to EP4 receptor; and a pharmaceutical product which contains the compound. Specifically disclosed is a compound represented by formula (1) (wherein R and R each independently represents a hydrogen atom or a linear alkyl group having 1-3 carbon atoms, and R represents a hydrogen atom, an alkyl group having 1-4 carbon atoms, an alkoxyalkyl group, an aryl group, a halogen atom or a halogenated alkyl group) or a pharmaceutically acceptable salt thereof, which is different from publicly known PGIs and has a selective EP4 agonist action. Consequently, a pharmaceutical product which contains the compound is useful for prophylaxis and/or treatment of immune diseases, cardiovascular diseases, heart diseases, respiratory diseases, eye diseases, kidney diseases, hepatic diseases, bone diseases, digestive tract diseases, neurological diseases, skin diseases and the like.

The invention provides an application of health care drinking liquid containing deep seawater in the preparation of medicaments or health care products for preventing or treating hyperlipoidemia. The health care drinking liquid comprises A liquid and B liquid, wherein the A liquid is of fresh water, the B liquid is of high-concentration concentrated liquid which is obtained by performing decompression concentration on a concentrated water part which is separated from the deep sweater via a reverse osmosis device, and the hardness range is 200-1000ppm. The health care drinking liquid is given to a rat with the hyperlipoidemia, which is subjected to modeling by a high-fat emulsion, in a free drinking way, after the medicament is administrated for 28 days, the blood lipid level of the rat with the hyperlipoidemia can be significantly reduced, lipid peroxidation can be inhibited, the activity of lipoprotein metabolic enzymes, namely LCAT (lecithin-cholesterol acetyltransferase), LPL (lipoprotein lipase) and HL (hepatic lipase), can be significantly improved, and the state of lipid metabolism disorder in the rat with the hyperlipoidemia, as well as concurrent fatty liver and diabetes thereof, can be further improved. The health care drinking liquid is derived from the deep seawater, has the advantages of abundant resources, easiness in industrialization and the like, and further has broad market and application prospects in the aspect of preventing and treating the hyperlipoidemia.

The present invention belongs to the field of medicine technology, and is especially a kind of medicine composition and its preparation process. The medicine composition is prepared with kurarinone 4-400 weight portions, glutathione 3-300 weight portions, and tiopronin 1-100 weight portions. The medicine composition may be prepared into different pharmaceutically acceptable forms, preferably injection and oral preparation. It has the pharmacological activities of antagonizing virus, improving liver cell function, antagonizing liver fibrosis, regulating immunity, diminishing inflammation, etc. and may be used in treating various hepatic diseases, viral hepatosis, medicinal hepatosis, alcoholic hepatosis, etc.

The invention discloses a preparation method of a lipid-lowering corbicula fluminea shell powder compound feed. The preparation method specifically comprises the steps of firstly, adding corbicula fluminea shell powder into a basal feed for culturing fish, wherein the adding amount of the corbicula fluminea shell powder accounts for 0.75%-3.25% of the total weight of the basal feed; then uniformly mixing the basal feed, namely corbicula fluminea shell powder, to prepare particles, and drying to obtain the compound feed. The feed prepared by the invention can be used for not only lowering the index of the fish liver and serum triglyceride, but also obviously improving the activity of hepatic lipase.

The invention discloses an application of a composition in preparation of a medicine for treating skin itching caused by hepatic diseases, wherein the composition is composed of medicinal alcohol and glycerol in a volume ratio of (3-1):1. The composition is formed by simply mixing alcohol and glycerol, does not generate any newborn substance, has a good effect on treating skin itching caused by hepatic diseases, does not cause irritation to skin itching caused by hepatic diseases, and can also play a role in protecting the skin.

The invention belongs to the field of medicine compositions and particularly relates to a medicinal and edible composition for treating a hepatic disease with malnutrition, a preparation and a preparation application. The composition comprises the following ingredients: Chinese wolfberries, Chinese yams, hawthorns, malt and semen raphani. The traditional Chinese medicine preparation comprises the medicinal and edible composition as an active ingredient and an auxiliary material. A reagent kit comprises traditional Chinese medicine preparation reagent units, wherein an effective dose of the medicinal and edible composition of each reagent unit is 0.1-3g. The invention further provides the application of the medicinal and edible composition or the traditional Chinese medicine preparation or the reagent kit in the field of preparing a medicine for treating the hepatic disease with the malnutrition or the field of preparing a health care product or food for protecting a liver. The medicinal and edible composition has multiple effects of supplementing nutrients, improving a liver function, improving an appetite and relieving abdominal distention, is good in safety and taste and low in price, and has obvious advantages in nutritional supplementation for a patient with the hepatic disease.

The invention relates to the technical field of biochemical detection, in particular to a reagent used for measuring pancreatic lipase in serum or plasma, and a preparation method and application thereof. The invention provides pancreatic lipase measurement reagent which comprises sodium dodecyl sulfate, protamine sulfate and sphingomyelin. Since the sodium dodecyl sulfate, the protamine sulfate and the sphingomyelin are added into the pancreatic lipase measurement reagent, the interference function of hepatic lipase, lipoprotein lipase and cholesterol esterase in the serum for pancreatic lipase measurement can be obviously lowered, nonspecific lipolysis reaction in the serum or the plasma in a reaction process of the pancreatic lipase measurement can be effectively inhibited, meanwhile, the catalytic activity of the pancreatic lipase can guarantee to be effectively performed, pancreatic lipase measurement specificity and accuracy is improved, and the false positive rate of pancreaticlipase detection is effectively lowered.

The invention discloses a purpose of lachnum melanin, namely the application in preparation of a blood fat-reducing medicament. The lachnum melanin is the intracellular melanin LM of lachnum YM226. Pharmacological experiments prove that the LM can effectively reduce the body weight of a high-fat mouse; the levels of TC (Total Cholesterol), TG (Triglyceride) and LDL-C (Low Density Lipoprotein Cholesterin) in the serum and the liver and an AI (Atherogenic Index) of the mouse can be effectively reduced; meanwhile, the HDL-C level is improved; in addition, the activity of antioxidant enzyme SOD (Superoxide Dismutase), GHS-PX (Glutathione Peroxidase), HL (Hepatic Lipase) and LPL (Lipoprotein Lipase) in the serum and the liver of the mouse is remarkably improved by the LM; the content of MDA (Malondialdehyde) is reduced; moreover, the levels of ALT (Alanine Transaminase), AST (Aspartate Transaminase), ALP (Alkaline Phosphatase), CRE (Cre Recombinas), BUN (Blood Urea Nitrogen) and Uric acid are reduced. The LM improves liver and kidney dysfunction caused by hyperlipidemia, shows a remarkable effect on reducing blood fat, does not have a toxic or side effect, can be used for preparing theblood fat-reducing medicament, and is prepared into various preparations according to conventional preparation methods in pharmaceutics, so as to be convenient to take.

The invention provides application of yellow thorn fruits or extracts of the fruits to preparing medicines or health care products or food for treating dyslipidemia. The research shows that the yellow thorn fruits have the effect of treating the dyslipidemia, and cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL) and rising high-density lipoprotein (HDL) can be reduced; the enzymatic activity relevant to lipid metabolism can be improved, that is, the activity of the lipoprotein lipase and hepatic lipase can be improved; meanwhile, the activity of glutamic oxalacetic transaminase and glutamic-pyruvic transaminase can be reduced, no hurt to the liver tissue exists, and the fruits can be used as the good-safety medicines or the health care products or the food for treating the dyslipidemia.